Full article view2017-09-21T08:01:31+00:00

Q&A With Precision’s Scott Marshall in Drug Discovery & Development: Biomarkers Can Inform Early-Stage Clinical Trial Design

 

Precision for Medicine’s Scott Marshall, managing director, Translational Informatics & Diagnostics, participates in a Q&A with Drug Discovery & Development’s Ryan Bushey. Marshall outlines the benefits biomarkers can yield in early-stage trials.

To read the complete interview, click here.

Precision Medicine Group is an integrated team of experts in fields from advanced lab sciences to translational informatics and regulatory affairs, payer insights to marketing communications. Together, we help our pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.

By continuing to use our website, you agree to our use of cookies to help us give you the best experience, analyze your site usage, and assist in our marketing efforts.
For more information, or to learn how to change your cookies preferences, please click here.

OK